GLP-1 Drugs are Rewriting the Rules of Health, Wealth, & Who Gets Treated
- Abigail Hahm
- Apr 16
- 5 min read
GLP-1s, once a quiet revolution in type 2 diabetes mellitus (T2DM) management since their 2005 approval, have detonated onto the mainstream, their purpose and perception utterly transformed. Initially designed to stimulate insulin, suppress glucagon, slow digestion, and induce satiety—collectively improving blood sugar and cardiovascular health—these medications have now donned a new mantle: chronic weight management. This seismic shift has propelled drugs like Ozempic, Mounjaro, Wegovy, and Zepbound, originally diabetes mainstays, into the spotlight as highly sought-after weight-loss solutions, frequently prescribed even in the absence of a diabetes diagnosis.
The rise in off-label use, fueled by social media, celebrity endorsements, and a growing wellness culture, has created an avalanche of demand, stretching supply chains and reshaping public perception of what constitutes a healthy lifestyle.
GLP-1s have proven effective in aiding weight loss by influencing neural pathways related to appetite and reward, leading to increased satiety and reduced hunger. For individuals living with obesity, this poses a glimmer of hope for medical support in managing a complex, chronic condition. However, the rapid surge in prescriptions, especially among non-diabetic populations, raises some ethical, medical, and systemic questions.
Recent data starkly illustrate this phenomenon, revealing that a significant 56% of Ozempic and Mounjaro users lacked a T2DM diagnosis, while a larger 81% of Wegovy recipients were using the drug on-label for obesity. Alarmingly, this demand has spawned a black market of compounded, non-FDA-approved versions, despite explicit warnings from regulatory bodies, with over 775 adverse event reports linked to these unregulated concoctions by February 2025.
GLP-1 medications are not without side effects. Patients often experience gastrointestinal issues, nausea, vomiting, low blood sugar, and, in rare cases, pancreatitis. The long-term effects, especially among non-diabetic users, remain unclear due to the lack of longitudinal studies.
More troubling is the way these drugs have been marketed and popularized by healthcare professionals, often targeting young women aged 18–25, a demographic already vulnerable to disordered eating, body image issues, and weight stigma. The use of GLP-1s has started becoming a trendy fix, not a medically guided intervention. Celebrities and influencers tout weight loss results, while overlooking the risks and nuances. What was meant to be a tool for managing chronic disease is now a status symbol of slimness—a distortion that requires precaution and real consequences.
The rise in off-label and aesthetic-driven prescriptions has led to shortages that disproportionately harm diabetic patients. Despite the FDA declaring no current shortage of Zepbound or Mounjaro in 2024, perceptions and past availability issues persist. Diabetic patients have faced difficulty filling prescriptions, often left with fewer options due to the overwhelming surge in demand for weight loss purposes.
Meanwhile, pharmacies and manufacturers profit off the hype, while insurers like Medicare and Medicaid in some states have withdrawn coverage for weight-loss-related prescriptions. This has left many patients navigating medical loopholes, leveraging borderline diagnoses, or paying out of pocket—up to $800 per month—to access these drugs. The result? A healthcare system where those who need the medication most are pushed to the margins.
GLP-1s offer real medical benefits for those with medical needs. They can reduce obesity-related complications and potentially ease the economic burden of chronic illness, lost productivity, and rising healthcare costs. But their meteoric rise prompts critical questions:
Are we medicalizing weight loss or finally treating obesity as a serious, chronic disease?
Are GLP-1s a tool for health or a shortcut for aesthetic goals?
Is our healthcare system equipped to prioritize need over profit, or are we headed toward a future of pharmaceutical trend-chasing?
According to the Center for Human Nutrition, “a permanent change in the environment is the best way to ensure permanent changes”—a sentiment that underscores the limitations of relying solely on obesity medications. While some individuals may be genetically predisposed to weight gain, for the majority, meaningful improvements come from adopting healthier eating habits and increasing physical activity. Medications alone are unlikely to lead to lasting change. That’s not to say these drugs don’t have value—but they should be viewed as one component of a larger, more comprehensive approach to health, not the cornerstone
GLP-1 agonists were designed to help those battling diabetes and chronic disease, but they are now redefining the obesity treatment landscape. This new era raises urgent ethical, medical, and social questions about access, intention, and the future of preventive versus reactive medicine.
In the pursuit of health, are we redefining medicine—or simply reshaping it to suit our desires?
Read more about the impact of federal research funding cuts on the future of medicine and learn about the most anticipated drug launches of 2025.
Further Reading:
If you liked this article:
Share this article with your network on LinkedIn with your thoughts or perspectives. Make sure to tag us @HealthcareInsights to join the conversation.
Subscribe to our free newsletter, HealthcareIn Quicktakes. You'll never miss an article, and will get access to exclusive reports.
Check out our library of articles and reports on biotech, healthcare, policy, and business.
Who We Are: At Healthcare Insights, we're covering the transformation of healthcare and bringing our readers the most pertinent takes on key issues in medicine, biotech, healthcare policy, and business. Our Spotlight Series ✦ features thoughts from the most influential figures in healthcare, including Nobel Prize-winning scientists shaping tomorrow's treatments and business leaders bringing new therapies to market. We strive to publish coverage that is authentic, impartial, and independent of any financial or political motive. For more information regarding our editorial standards, read our statement. If you'd like to contact the Editor, use this form to get in touch.
If you'd like to stay in the loop, make sure to subscribe to our free newsletter, HealthcareIn Quicktakes, and follow us @healthcareinsightsny across our social channels, including LinkedIn.
©️ Copyright 2025 Healthcare Insights
All Rights Reserved
Legal Disclaimer:
The information provided in this article has been collected from various academic publications, industry reports/analyses, regulatory guidelines, media coverage, and legal analyses. The information provided is for general information purposes only and should not be construed for medical, legal, financial, or professional advice. Readers are advised to seek independent professional guidance where relevant. While we strive to ensure the accuracy and timeliness of our coverage, we claim no liability, representations, or warranties of any kind about the completeness, suitability, accuracy, reliability, authorship, or availability of this article and all pertaining data within this article. Neither the author nor the publication will assume liability for any loss or damage arising from the use of the information provided in the article. The information within this article may be outdated or inaccurate over time, and neither the author nor the publication are obligated to update or revise such information. We reserve the right to modify, remove, or substantially edit the article, including the disclaimer, at any time.
Commentaires